Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Diadexus logo — company profile

Diadexus

Founded 1997 23 employees Post-IPO Debt Total: $171.20M Biotechnology, Health Care

General Information

Company Name Diadexus
Founded Year 1997
Employees 23
Industries Biotechnology, Health Care
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Diadexus. To contact Diadexus, visit diadexus.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Diadexus compare?

A PDF of Diadexus and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Diadexus soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Diadexus

Diadexus is a biotechnology and healthcare company founded in 1997. The company focuses on developing and commercializing diagnostic products to aid in predicting cardiac disease risk, providing healthcare providers with actionable information for managing patients. Diadexus is known for pioneering the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), which is a marker of vascular-specific inflammation that offers new information beyond traditional risk factors measured in a lipid panel. The company's products, the PLAC® Test ELISA Kit and the PLAC® Test for L-PLA2 Activity, are the only two FDA-cleared tests to measure Lp-PLA2. Additionally, Diadexus is working on a pipeline of advanced cardiac biomarkers including biomarkers for heart failure such as proADM, proET-1, and proANP, each providing distinct and additive information for healthcare providers. The company also offers services to pharmaceutical partners to incorporate biomarkers in clinical development. Their portfolio of advanced cardiac biomarkers can be paired with novel therapeutics to provide valuable insights for indications where cardiovascular risk information is crucial. Diadexus received a $15.00M post-IPO debt investment on 18 August 2014 from Oxford Finance LLC, demonstrating investor confidence in the company's potential for growth and impact in the healthcare industry.

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $15.00M 1
Oxford Finance LLC
18 Aug 2014
Post IPO Debt $4.50M -
08 Jun 2010
Post IPO Equity $9.20M 3
Scale Venture Partners GlaxoSmithKline
Scale Venture Partners, GlaxoSmithKline +1
06 Feb 2009
Post IPO Equity $40.00M 6
Scale Venture Partners Rho Capital Partners GlaxoSmithKline
Scale Venture Partners, Rho Capital Partners +4
12 Jan 2007
Post IPO Equity $102.50M -
11 Apr 2000

Diadexus Alternatives & Competitors

View All Alternatives
Diadexus vs
Aspira Women's Health
Aspira Women's Health United States

Globally transforming women's health, starting with ovarian cancer.

Post-IPO Equity
66 employees
Biotechnology, Health Care
Diadexus vs
Biobeat
Biobeat Israel

AI remote patient monitoring platform, measuring 13 vital signs and triggering early clinical interv...

Series A
35 employees
Biotechnology, Data Analytics
Diadexus vs
Tiny Health
Tiny Health

There are 38 trillion reasons to care about your microbiome

Series A
66 employees
Biotechnology, Health Care
View all alternatives

FAQ About Diadexus

A Multi-Product Company Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phosp...
Diadexus was founded in 1997.
Diadexus operates in Biotechnology and Health Care.
Diadexus has approximately 23 employees.
Diadexus has completed 5 funding rounds, raising a total of $171.20M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Diadexus include Aspira Women's Health, Biobeat, Tiny Health, Geneoscopy, BioWave Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Diadexus and Aspira Women's Health are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Diadexus, https://bouncewatch.com/company/diadexus, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout